Arndt Vogel: Zenocutuzumab in Rare NRG1 Fusion-Positive Cholangiocarcinoma
Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X: Title: Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive…
Read the full articleYou might also wanna read
HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
Conditions : Liver Cancer Interventions : Device: DEB-TACE; Drug: Toripalimab; Drug: Lenvatinib; Drug: Gemcitabine; Drug: Oxaliplatin Sponso
A Phase III Trial of Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Conditions : Intrahepatic Cholangiocarcinoma (Icc) Interventions : Drug: Gemcitabine; Drug: Cisplatin; Drug: Tislelizumab; Drug: Lenvatinib;
Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
Conditions : Gastric Cancer; Gastroesophageal Junction (GEJ) Adenocarcinoma; Becotatug Vedotin; Pucotenlimab Interventions : Drug: Becotatug
A Study of Combination Therapy in Patients With Resectable Liver Cancer
Conditions : Liver Cancer (Primary and Metastatic) Interventions : Drug: Hepatic Arterial Infusion Chemotherapy Combined with Adebrelimab Pl
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
Conditions : Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; HER2-positive Gastric Cancer Interventions : Drug: Zanidatamab; Drug:
A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.
Conditions : Biliary Tract Neoplasms Immunotherapy Interventions : Combination Product: Durvalumab plus GEMOX/GC chemotherapy sequentially f
Comments
Sign in to join the conversation.
No comments yet. Be the first.